Ascendis Pharma A (ASND) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$62.8 million.
- Ascendis Pharma A's Consolidated Net Income rose 4110.4% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 4700.19%. This contributed to the annual value of -$398.7 million for FY2024, which is 2302.61% up from last year.
- Latest data reveals that Ascendis Pharma A reported Consolidated Net Income of -$62.8 million as of Q3 2025, which was up 4110.4% from -$35.3 million recorded in Q2 2025.
- In the past 5 years, Ascendis Pharma A's Consolidated Net Income ranged from a high of -$35.3 million in Q2 2025 and a low of -$200.7 million during Q4 2022
- Moreover, its 5-year median value for Consolidated Net Income was -$117.3 million (2024), whereas its average is -$113.5 million.
- Per our database at Business Quant, Ascendis Pharma A's Consolidated Net Income plummeted by 8596.18% in 2022 and then soared by 6993.03% in 2025.
- Over the past 5 years, Ascendis Pharma A's Consolidated Net Income (Quarter) stood at -$121.3 million in 2021, then tumbled by 65.42% to -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then skyrocketed by 52.12% to -$38.8 million in 2024, then plummeted by 62.01% to -$62.8 million in 2025.
- Its Consolidated Net Income stands at -$62.8 million for Q3 2025, versus -$35.3 million for Q2 2025 and -$97.3 million for Q1 2025.